Lung Cancer | Specialty

New Paradigms for Treatment of Locally Advanced NSCLC

March 13th 2018

Dr. Clarke on the State of Biomarkers in NSCLC

March 13th 2018

Jeffrey M. Clarke, MD, assistant professor of medicine, Duke Cancer Institute, discusses the evolution of biomarkers in directing treatment for patients with non–small cell lung cancer (NSCLC).

Dr. Pecot on Immunotherapy Combinations in NSCLC

March 13th 2018

Chad Pecot, MD, assistant professor, School of Medicine, UNC Lineberger Comprehensive Cancer Center, discusses promising combinations for patients with non–small cell lung cancer (NSCLC).

Naidoo Discusses Advances in the Management of Immunotherapy-Related AEs

March 13th 2018

Jarushka Naidoo, MBBCh, discusses some of the most commonly seen immune-related adverse events in patients with lung cancer and how to manage them.

Dr. Lopes Discusses the Importance of Addressing Financial Toxicity in Lung Cancer

March 13th 2018

Gilberto Lopes Jr, MD, a medical director for International Programs at Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the important of addressing financial toxicity during the 5th Annual Miami Lung Cancer Conference.

Novel Agents Emerging for Lesser-Known Targets in NSCLC

March 13th 2018

ROS1, NTRK, MET, and HER2 are all less common molecular targets found in non–small cell lung cancer, but emerging therapeutic strategies are being explored to attack these abnormalities.

Expert Discusses Developments, Challenges With Radiation in NSCLC

March 13th 2018

Holger L. Gieschen, MD, discusses the latest developments with radiation therapy in non-small cell lung cancer.

Dr. Wakelee on First-Line Therapy for EGFR-Mutant Lung Cancer

March 12th 2018

Heather Wakelee, MD, professor of medicine, division of oncology, Stanford University, discusses first-line therapy for patients with EGFR-mutant lung cancer.

BRAF V600E Testing Necessary in NSCLC, but Experts Unsure of Optimal Setting With BRAF/MEK Combo

March 12th 2018

Upfront testing for BRAF V600E mutations is necessary for patients with non–small cell lung cancer, but if results are positive, physicians are unsure when to administer BRAF/MEK combination therapy—and they must be prepared to manage the associated adverse events.

Dr. Weiner on Radiotherapy Trials in NSCLC

March 12th 2018

Ashley A. Weiner, MD, PhD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses clinical trials that have investigated the use of radiotherapy in patients with non–small cell lung cancer (NSCLC).

Wakelee Discusses Debate Surrounding Osimertinib in Frontline EGFR-Mutant Lung Cancer

March 11th 2018

Heather Wakelee, MD, discusses the rapidly changing landscape of frontline EGFR tyrosine kinase inhibitors in non–small cell lung cancer.

Dr. Naidoo Discusses the Management of Immune-Related Adverse Events in Lung Cancer

March 11th 2018

Jarushka Naidoo, MBBCh, assistant professor of oncology, Johns Hopkins University, discusses advancements in the management of immune-related adverse events (irAEs) in patients with lung cancer during the 5th Annual Miami Lung Cancer Conference.

Dr. Brahmer Discusses Frontline Single-Agent Pembrolizumab in Lung Cancer

March 11th 2018

Julie R. Brahmer, MD, associate professor of oncology, co-director of the Upper Aerodigestive Department, Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses pembrolizumab (Keytruda) in the first-line treatment of non–small cell lung cancer during the 5th Annual Miami Lung Cancer Conference.

Immunotherapy Making Headway in SCLC and Mesothelioma

March 11th 2018

Immune-based therapies continue to show promising signals for patients with small cell lung cancer and mesothelioma, but better predictive biomarkers are needed to determine who is most likely to benefit.

Studies Highlight Rationale for Immunotherapy in Early-Stage and Locally Advanced NSCLC

March 11th 2018

With durvalumab (Imfinzi) being hailed as a potentially practice changing therapy in locally advanced non–small cell lung cancer, ongoing studies are seeking to determine the efficacy of immunotherapy in earlier stages of disease.

Dr. Stinchcombe on Advances in Targeted Therapies in NSCLC

March 10th 2018

Thomas E. Stinchcombe, MD, professor of medicine, Duke Cancer Institute, discusses pivotal trials that have reshaped the standard of care in non–small cell lung cancer (NSCLC).

Dr. Long on Surgical Advances in NSCLC

March 10th 2018

Jason M. Long, MD, assistant professor of surgery, Division of Cardiothoracic Surgery, University of North Carolina at Chapel Hill, discusses specific minimally invasive thoracic surgery approaches in lung cancer.

Expert Sheds Light on Future of Targeted Treatment in NSCLC

March 9th 2018

David C. Portnoy, MD, discusses emerging developments with targeted agents in lung cancer.

Dr. Weiss on the Design of the PACIFIC Trial

March 9th 2018

Jared Weiss, MD, associate professor, School of Medicine, UNC Chapel Hill, UNC Lineberger Comprehensive Cancer Center, discusses the clinical applications of the phase III PACIFIC trial in non–small cell lung cancer in the United States.

Dr. Schwartzberg on Emerging Biomarkers in NSCLC

March 8th 2018

Lee S. Schwartzberg, MD, FACP, chief and professor, Division of Hematology/Oncology, the University of Tennessee Health Science Center, medical director, West Clinic, executive director, West Cancer Center, discusses several emerging biomarkers in non–small cell lung cancer (NSCLC).